Neglected Tropical Disease News and Research

RSS

Large public-private partnership announced to speed progress against NTDs

Thirteen pharmaceutical companies; the governments of the U.S., U.K. and United Arab Emirates; the Bill & Melinda Gates Foundation; the WHO; the World Bank; the Drugs for Neglected Diseases initiative (DNDi); and other global health organizations "announced a new, coordinated push to accelerate progress toward eliminating or controlling 10 neglected tropical diseases (NTDs) by the end of the decade," according to a press release from Global Health Strategies.

31 Jan 2012

Abbott, DNDi partner to research on new treatments for NTDs

The Drugs for Neglected Diseases initiative (DNDi) and Abbott have signed a four-year joint research and non-exclusive licensing agreement to undertake research on new treatments for several of the world's most neglected tropical diseases, including Chagas disease, helminth infections, leishmaniasis and sleeping sickness.

31 Jan 2012

WHO to convene meeting on yaws eradication efforts based on study of oral treatment

"Findings that a one-time oral treatment to cure yaws, a neglected tropical disease, is as effective as the currently recommended penicillin injection have prompted the World Health Organization (WHO) to convene a meeting on how the disease may be wiped out," IRIN reports.

13 Jan 2012

Social media faster than traditional sources in tracking cholera in Haiti, study says

"Internet-based news and Twitter feeds were faster than traditional sources at detecting the onset and progression of the cholera epidemic in post-earthquake Haiti ..., according to a new study published in the January issue of the American Journal of Tropical Medicine and Hygiene (AJTMH)," an AJTMH press release states.

11 Jan 2012

SCYNEXIS, MMV assemble Malaria Box of 400 compounds with antimalarial activity

In a bid to catalyse malaria and neglected disease drug discovery, MMV and SCYNEXIS, Inc. have assembled a Malaria Box of 400 carefully selected commercially available compounds with antimalarial activity and will provide it to researchers at no cost.

20 Dec 2011

New pediatric formula for Chagas disease treatment developed in Brazil

"A new pediatric formulation developed in Brazil holds out hope for a cure for over 90 percent of newborn babies infected with Chagas disease, a parasitic infection endemic in 21 Latin American countries, where it kills more people every year than malaria," Inter Press Service reports.

9 Dec 2011

Global health R&D funding from wealthy nations fell 6% in 2010, annual G-FINDER report finds

"A group that tracks funding for neglected diseases released its fourth annual report Wednesday, showing for the first time since 2007 a decrease in government and public spending in global health research and development," the Center for Global Health Policy's "Science Speaks" blog reports.

8 Dec 2011

Brazil's ANVISA grants registration for child-adapted formulation of benznidazole for Chagas disease

Today, at the occasion of the 4th DNDi Partners' Meeting in Rio de Janeiro, Brazil, Dr Carlos Gadelha, Secretary of Science, Technology and Strategic Products, Brazilian Ministry of Health, announced that Brazil's National Health Surveillance Agency (ANVISA) granted registration of a new paediatric dosage form of benznidazole, developed through a partnership between the Pernambuco State Pharmaceutical Laboratory (LAFEPE) of Brazil and the Drugs for Neglected Diseases initiative (DNDi).

3 Dec 2011

DNDi highlights lack of healthcare coverage for children with HIV/AIDS

Less than one-quarter (23%) of children with HIV/AIDS who need treatment are getting it, according to a report released by the World Health Organization (WHO) on the occasion of World AIDS Day.

2 Dec 2011

Five ways pharmaceutical companies can address NTDs

In this Forbes opinion piece, journalist Sarika Bansal examines five ways in which pharmaceutical companies can address neglected tropical diseases (NTDs), including creating cross-sectorial research partnerships for neglected diseases; joining patent pools for neglected diseases; donating drugs for neglected diseases; creating facilities dedicated to neglected disease research; and allowing scientists to work on neglected disease, both formally and informally.

24 Nov 2011

Oral antibiotics might treat Buruli ulcer

It might be possible to treat Buruli ulcer, a crippling and deforming disease, with only oral medicines, which would make treatment easier. And even the current treatment can in many cases be given in an outpatient regimen.

23 Nov 2011

Streamlining clinical trials review process to speed up delivery of drugs to those in need

In this Atlantic opinion piece, Amanda Glassman, director of Global Health Policy at the Center for Global Development (CGD), reports on how lengthy, inefficient review processes for drug and vaccine candidates waiting in the pipeline for late stages of clinical development is keeping promising new medicines, vaccines, and diagnostic techniques from reaching millions in need.

16 Nov 2011

Researchers to begin drug development projects for rare and neglected diseases

Researchers will begin drug development projects for rare and neglected diseases that include potential treatments for a musculoskeletal disorder, a cognitive dysfunction disorder, a virus that affects the central nervous system of newborns, a parasitic worm infection, a form of muscular dystrophy and a rare lung disease.

16 Nov 2011

IVI receives WHO prequalification for new oral cholera vaccine

Shanchol-, a new oral cholera vaccine developed through the International Vaccine Institute (IVI), an international organization established by the United Nations and based in Seoul, recently received prequalification from the World Health Organization.

13 Nov 2011

Pharmaceutical industry should invest more in NTDs

In this Forbes opinion piece, contributor Sarika Bansal examines "what needs to happen for the pharmaceutical industry, academic researchers, and other key players to begin investing more seriously in" neglected tropical diseases.

11 Nov 2011

OWH to participate in major kala-azar elimination project

OneWorld Health (OWH) announced that it will participate in a major consortium project aimed to boost strategies for control and eventual elimination of visceral leishmaniasis (VL or kala-azar) in India and Bangladesh, where the disease burden is among the world's highest.

10 Nov 2011

Four-year kala azar treatment study launched in India, Bangladesh

"A four-year test of drugs to treat a widespread parasitic disease called kala azar was announced on Monday by the governments of India and Bangladesh, Doctors Without Borders, the Drugs for Neglected Diseases Initiative [DNDi] and other groups," the New York Times reports.

9 Nov 2011

CGD releases report on improving clinical trials, regulatory pathways for fighting neglected diseases

The Center for Global Development (CGD) last week released a new report on global health, the Global Health Technology Coalition's "Breakthroughs" blog reports.

8 Nov 2011

Largest-ever implementation study on kala-azar in Asia

A comprehensive four-year project including over 10,000 patients in clinical and pharmacovigilance studies for diagnosis and treatment of visceral leishmaniasis (VL, also known as kala-azar) in India and Bangladesh was launched by an international consortium formed last month to support control and elimination strategies in both countries, where the concentration of disease burden is among the world's highest.

7 Nov 2011

Global Health Technologies Coalition blog reports on health research projects in Kenya

In a post in the Global Health Technologies Coalition's "Breakthroughs" blog, GHTC's Kim Lufkin reports on her travels to Kenya this month "to visit global health research projects and see the impact on people in the country," writing, "Although we visited a range of projects, I was left with the lasting impression that much of this research is so close to producing new health tools that can lead to amazing innovations in public health," including "the first ever malaria vaccine, gels women can use to protect themselves from HIV, and new drugs for neglected diseases that affect the poorest of the poor."

29 Oct 2011